Eptifibatide Injection Recalled Over Labeling Error
Slate Run Pharmaceuticals recalled Eptifibatide Injection on February 12, 2026. The recall affects all lots of the 75 mg/100 mL vial due to incorrect dosing information. Healthcare providers and consumers must stop using the product immediately.
Product Details
Eptifibatide Injection comes in a 75 mg/100 mL single-dose vial for intravenous use. It is manufactured by Hainan Poly Pharm. Co., Ltd., and distributed by Slate Run Pharmaceuticals. The product carries NDC numbers 70436-027-80 and 70436-163-80.
The Hazard
The labeling on Eptifibatide Injection incorrectly states it is for weight-adjusted bolus dosing. The approved use is for weight-adjusted infusion. Using the product based on the incorrect label can put patients at risk for improper dosing.
What to Do
Consumers and healthcare providers should stop using Eptifibatide Injection immediately. Contact Slate Run Pharmaceuticals or your healthcare provider for guidance on the next steps.
Contact Information
For more information, consumers can contact Slate Run Pharmaceuticals at their customer service number or visit the FDA's website for updates.